Barbara et al. [89] employed CRISPR/Cas9 technology to induce MGMT reordering in glioma cells, discovering that genomic rearrangement permits regulation by more active promoters, leading to increased MGMT expression and enhancement of TMZ resistance. This evidence concerns the gene MGMT and glioma.